Updated: Mon, Sep 24 9:01 AM EDT
RICHMOND, BC, Sept. 24 /PRNewswire/ - (TSE:IZP) - Inflazyme Pharmaceuticals Ltd. today announced that it has received approval in the United Kingdom to commence two separate Phase I human clinical trials with two new oral anti-inflammatory compounds: IPL550,260 and IPL512,602.
IPL550,260 and IPL512,602 are structurally diverse compounds that have been derived from a new class of leukocyte suppressing compounds discovered and developed by scientists at Inflazyme. In pre-clinical studies, compounds in the class exhibit a general anti-inflammatory effect via inhibition of leukocyte (white blood cell) accumulation at the inflammatory site.
"The Phase I clinical studies are designed to study pharmacokinetics, safety and tolerability of these new drugs in human volunteers," said Ian McBeath, President and CEO of Inflazyme Pharmaceuticals Ltd. "At present we are developing these new molecules as general anti-inflammatory agents," added McBeath, "however, upon completion of concurrent ongoing pre-clinical models, we will announce specific disease indications prior to the commencement of Phase II trials".
"Leukocytes are an important component of the inflammatory process," said McBeath. An inflammatory response is provoked when an insult occurs to a tissue. At this time, leukocytes move from the blood to the inflammatory site where they release mediators that contribute to the damage and pathology of diseases such as asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis and others. By inhibiting the process of leukocyte infiltration, Inflazyme's compounds may have application in a broad range of diseases.
Inflazyme's lead compound IPL576,092, is also a novel leukocyte suppressing anti-inflammatory drug. This compound is currently in Phase II clinical studies as a potential new oral therapy for asthma. These studies are targeted for completion at the end of 2001. "With the commencement of the clinical trials for the two new compounds Inflazyme will have three separate and distinct drug candidates in the clinic for the treatment of inflammatory diseases," said McBeath. "This moves the Company further towards its goal of becoming a leader in the treatment of inflammation."
Inflazyme is developing one of its compounds as a treatment for asthma and respiratory disease in collaboration with Aventis Pharma.
Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for the treatment of inflammatory disease.
Inflazyme is a member of the TSE 300 Composite index.
Further information on the Company may be obtained from its website at http://wwwinflazyme.com
The statements made in this press
release contain certain forward-looking comments. Actual events or results
may differ from the Company's expectations. No assurance can be given that
the Company will obtain the necessary approvals to enable the commencement
or continuation of human clinical testing in a timely manner or at all.
In addition to the matters described in the press release, future actions
by the U.S. Food and Drug Administration or equivalent regulatory authorities
in other countries and results of pending or future clinical trials may
affect the actual results achieved by the Company. The Toronto Stock Exchange
has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
©2001 At Home Corporation
©2001 At Home Corporation